These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36813089)

  • 21. Biopharmaceutic
    Arora S; Pansari A; Kilford P; Jamei M; Gardner I; Turner DB
    Mol Pharm; 2020 Jul; 17(7):2329-2344. PubMed ID: 32427480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Itraconazole Amorphous Solid Dispersion Tablets: Formulation and Compaction Process Optimization Using Quality by Design Principles and Tools.
    Triboandas H; Pitt K; Bezerra M; Ach-Hubert D; Schlindwein W
    Pharmaceutics; 2022 Nov; 14(11):. PubMed ID: 36365216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
    Mudie DM; Stewart AM; Biswas N; Brodeur TJ; Shepard KB; Smith A; Morgen MM; Baumann JM; Vodak DT
    Mol Pharm; 2020 Dec; 17(12):4463-4472. PubMed ID: 32835489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.
    Van Den Abeele J; Kostantini C; Barker R; Kourentas A; Mann JC; Vertzoni M; Beato S; Reppas C; Tack J; Augustijns P
    Eur J Pharm Sci; 2020 Aug; 151():105377. PubMed ID: 32461076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of amorphization and GI physiology on supersaturation and precipitation of poorly soluble weakly basic drugs using a small-scale in vitro transfer model.
    Auch C; Jede C; Harms M; Wagner C; Mäder K
    Int J Pharm; 2020 Jan; 574():118917. PubMed ID: 31811926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
    Stillhart C; Parrott NJ; Lindenberg M; Chalus P; Bentley D; Szepes A
    AAPS J; 2017 May; 19(3):827-836. PubMed ID: 28236228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining lipid based drug delivery and amorphous solid dispersions for improved oral drug absorption of a poorly water-soluble drug.
    Nora GI; Venkatasubramanian R; Strindberg S; Siqueira-Jørgensen SD; Pagano L; Romanski FS; Swarnakar NK; Rades T; Müllertz A
    J Control Release; 2022 Sep; 349():206-212. PubMed ID: 35787914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioequivalence Comparison of Pediatric Dasatinib Formulations and Elucidation of Absorption Mechanisms Through Integrated PBPK Modeling.
    Vaidhyanathan S; Wang X; Crison J; Varia S; Gao JZH; Saxena A; Good D
    J Pharm Sci; 2019 Jan; 108(1):741-749. PubMed ID: 30439460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PBPK modeling coupled with biorelevant dissolution to forecast the oral performance of amorphous solid dispersion formulations.
    Kambayashi A; Kiyota T; Fujiwara M; Dressman JB
    Eur J Pharm Sci; 2019 Jul; 135():83-90. PubMed ID: 31125680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential prediction of formulation performance in paediatric patients using biopharmaceutical tools and simulation of clinically relevant administration scenarios of nifedipine and lorazepam.
    Van der Vossen AC; Hanff LM; Vulto AG; Fotaki N
    Br J Clin Pharmacol; 2019 Aug; 85(8):1728-1739. PubMed ID: 30964947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of Oral Flexible Tablet (OFT) Formulation for Pediatric and Geriatric Patients: a Novel Age-Appropriate Formulation Platform.
    Chandrasekaran P; Kandasamy R
    AAPS PharmSciTech; 2017 Aug; 18(6):1972-1986. PubMed ID: 27921260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.
    Pas T; Verbert S; Appeltans B; Van den Mooter G
    Int J Pharm; 2020 Jan; 573():118884. PubMed ID: 31786356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Effect of Inorganic Salt on Disintegration of Tablets with High Loading of Amorphous Solid Dispersion Containing Copovidone.
    Xi H; Ren J; Novak JM; Kemp E; Johnson G; Klinzing G; Johnson MA; Xu W
    Pharm Res; 2020 Mar; 37(4):70. PubMed ID: 32185516
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopredictive capability assessment of two dissolution/permeation assays, µFLUX™ and PermeaLoop™, using supersaturating formulations of Posaconazole.
    Holzem FL; Weck A; Schaffland JP; Stillhart C; Klein S; Bauer-Brandl A; Brandl M
    Eur J Pharm Sci; 2022 Sep; 176():106260. PubMed ID: 35842141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biopharmaceutical implications of excipient variability on drug dissolution from immediate release products.
    Zarmpi P; Flanagan T; Meehan E; Mann J; Østergaard J; Fotaki N
    Eur J Pharm Biopharm; 2020 Sep; 154():195-209. PubMed ID: 32681966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring the use of modified in vitro digestion assays for the evaluation of ritonavir loaded solid lipid-based formulations.
    Andreadis II; Schulzen A; Quodbach J; Bergström CAS
    Eur J Pharm Sci; 2023 Oct; 189():106524. PubMed ID: 37433412
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges and Strategies for Solubility Measurements and Dissolution Method Development for Amorphous Solid Dispersion Formulations.
    Hermans A; Milsmann J; Li H; Jede C; Moir A; Hens B; Morgado J; Wu T; Cohen M
    AAPS J; 2022 Dec; 25(1):11. PubMed ID: 36513860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Downstream processing of amorphous solid dispersions into orodispersible tablets.
    Kokott M; Klinken S; Breitkreutz J; Wiedey R
    Int J Pharm; 2023 Jan; 631():122493. PubMed ID: 36528189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular-Level Examination of Amorphous Solid Dispersion Dissolution.
    Faiz Afzal MA; Lehmkemper K; Sobich E; Hughes TF; Giesen DJ; Zhang T; Krauter CM; Winget P; Degenhardt M; Kyeremateng SO; Browning AR; Shelley JC
    Mol Pharm; 2021 Nov; 18(11):3999-4014. PubMed ID: 34570503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Formulating Amorphous Solid Dispersions: Impact of Inorganic Salts on Drug Release from Tablets Containing Itraconazole-HPMC Extrudate.
    Takano R; Maurer R; Jacob L; Stowasser F; Stillhart C; Page S
    Mol Pharm; 2020 Aug; 17(8):2768-2778. PubMed ID: 31794228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.